Rare codons capacitate Kras-driven de novo tumorigenesis

Area of Science:

• Oncogenesis
• Molecular Biology
• Genetics

Background:

• The KRAS gene is frequently mutated in human cancers, leading to an overactive, cancer-promoting protein.
• KRAS genes possess a unique characteristic of being rich in rare codons, which restrict protein production.

Purpose of the Study:

• To investigate the impact of KRAS's rare codon bias on the development of new tumors.
• To explore whether modifying rare codons in KRAS affects tumor formation and progression.

Main Methods:

• Synonymous mutations were introduced into exon 3 of the Kras gene in mice to convert rare codons into common ones, creating the Kras(ex3op) allele.
• Mice carrying the Kras(ex3op) allele were exposed to carcinogens to assess tumor development compared to control groups.
• Tumor incidence, mutation frequency, and mutation types in the Kras(ex3op) allele were analyzed.

Main Results:

• Mice with at least one copy of the Kras(ex3op) allele developed fewer tumors after carcinogen exposure.
• Tumors in these mice showed less frequent mutation of the Kras(ex3op) allele and harbored weaker oncogenic mutations.
• Higher expression of the Kras(ex3op) allele was linked to reduced tumorigenesis, inducing growth arrest when oncogenic and showing tumor-suppressive activity when unmutated.

Conclusions:

• The intrinsic rare codon bias of the KRAS gene plays a significant role in the development of cancer.
• Modulating KRAS codon usage can influence tumor initiation and progression, suggesting a potential therapeutic avenue.
• KRAS expression levels, influenced by codon bias, are critical in determining its oncogenic or tumor-suppressive functions.